Comparison of Observed Biochemical Recurrence-free Survival in Patients With Low PSA Values Undergoing Radical Prostatectomy and Predictions of Preoperative Nomogram

Urology

Volumn 73, Issue 5, 2009, Pages 1098-1103

  Berglund, Ryan K ^a   Stephenson, Andrew J ^b   Cronin, Angel M ^a   Vickers, Andrew J ^a   Eastham, James A ^a   Klein, Eric A ^b   Guillonneau, Bertrand D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY;

AGED; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65049090812     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.07.052     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
3. Roobol M.J., Kranse R., de Koning H.J., et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam). Urology 63 (2004) 309-315
4. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
5. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 (1994) 242-248
6. Johansson J.E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 277 (1997) 467-471
7. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
8. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469-474
9. Schroder F.H., van der Cruijsen-Koeter I., de Koning H.J., et al. Prostate cancer detection at low prostate specific antigen. J Urol 163 (2000) 806-812
10. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
11. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
12. Chun F.K., Karakiewicz P.I., Briganti A., et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 99 (2007) 794-800
13. Chun F.K., Karakiewicz P.I., Huland H., et al. Role of nomograms for prostate cancer in 2007. World J Urol 25 (2007) 131-142
14. Jang T.L., Han M., Roehl K.A., et al. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 67 (2006) 343-348
15. Freedland S.J., Mangold L.A., Epstein J.I., et al. Biopsy indication-A predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology 63 (2004) 887-891
16. Litwin M.S., Hays R.D., Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 (1995) 129-135
17. Gosselaar C., Roobol M.J., Roemeling S., et al. Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics. Prostate 67 (2007) 154-161
18. Bozeman C.B., Carver B.S., Caldito G., et al. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. Urology 66 (2005) 803-807
19. Vis A.N., Hoedemaeker R.F., Roobol M., et al. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate 47 (2001) 252-261
20. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
21. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
22. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
23. Leibovici D., Spiess P.E., Agarwal P.K., et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109 (2007) 198-204